MA32726B1 - Antagonistes phtalazine disubstituee de la voie de signalisation hedgehog - Google Patents

Antagonistes phtalazine disubstituee de la voie de signalisation hedgehog

Info

Publication number: MA32726B1
Authority: MA; Morocco
Prior art keywords: phtalazine; disubstituted; antagonists; signaling path; hedgehog signaling
Prior art date: 2008-11-03

Application number

MA33790A

Other languages

Arabic (ar)

English (en)

French (fr)

Inventor

Jolie Anne Bastian

Philip Arthur Hipskind

Daniel Jon Sall

Takako Wilson

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-03

Filing date

2011-04-22

Publication date

2011-10-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41566219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32726(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-04-22 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2011-10-02 Publication of MA32726B1 publication Critical patent/MA32726B1/fr

Links

239000005557 antagonist Substances 0.000 title abstract 2
230000009459 hedgehog signaling Effects 0.000 title abstract 2
150000003020 phtalazines Chemical class 0.000 title abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

MA33790A 2008-11-03 2011-04-22 Antagonistes phtalazine disubstituee de la voie de signalisation hedgehog MA32726B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11070308P	2008-11-03	2008-11-03
PCT/US2009/061573 WO2010062507A1 (en)	2008-11-03	2009-10-22	Disubstituted phthalazine hedgehog pathway antagonists

Publications (1)

Publication Number	Publication Date
MA32726B1 true MA32726B1 (fr)	2011-10-02

Family

ID=41566219

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA33790A MA32726B1 (fr)	2008-11-03	2011-04-22	Antagonistes phtalazine disubstituee de la voie de signalisation hedgehog

Country Status (29)

Country	Link
US (1)	US8404687B2 (2)
EP (1)	EP2364185B1 (2)
JP (1)	JP2012507535A (2)
KR (1)	KR101335746B1 (2)
CN (1)	CN102202737B (2)
AU (1)	AU2009320251C1 (2)
BR (1)	BRPI0921437A2 (2)
CA (1)	CA2742539C (2)
CL (1)	CL2011000979A1 (2)
CO (1)	CO6382123A2 (2)
CR (1)	CR20110202A (2)
CY (1)	CY1114023T1 (2)
DK (1)	DK2364185T3 (2)
EA (1)	EA018931B1 (2)
EC (1)	ECSP11011021A (2)
ES (1)	ES2418479T3 (2)
HR (1)	HRP20130527T1 (2)
IL (1)	IL211841A0 (2)
MA (1)	MA32726B1 (2)
MX (1)	MX2011004683A (2)
NZ (1)	NZ591945A (2)
PE (1)	PE20110433A1 (2)
PL (1)	PL2364185T3 (2)
PT (1)	PT2364185E (2)
SI (1)	SI2364185T1 (2)
TN (1)	TN2011000166A1 (2)
UA (1)	UA102115C2 (2)
WO (1)	WO2010062507A1 (2)
ZA (1)	ZA201102448B (2)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20090188A1 (es) *	2007-03-15	2009-03-20	Novartis Ag	Compuestos heterociclicos como moduladores de la senda de hedgehog
UA102250C2 (ru)	2008-04-29	2013-06-25	Эли Лилли Энд Компани	Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en)	2008-07-18	2010-02-18	Novartis Ag	Organic Compounds as Smo Inhibitors
MX2011005176A (es)	2008-11-17	2011-05-30	Lilly Co Eli	Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
CA2743483C (en)	2008-11-17	2014-03-11	Eli Lilly And Company	Tetrasubstituted pyridazine hedgehog pathway antagonists
AR077014A1 (es)	2009-06-19	2011-07-27	Lilly Co Eli	Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
WO2015073691A1 (en)	2013-11-14	2015-05-21	The Board Of Trustees Of The Leland Stanford Junior University	Methods for treating cancer by activation of bmp signaling
CN105985320B (zh) *	2015-02-11	2018-10-26	复旦大学	苄基酞嗪化合物及其制备方法和用途
CN105985319B (zh) *	2015-02-11	2019-02-26	复旦大学	芳基酞嗪化合物及其制备方法和用途
CN105985321B (zh) *	2015-02-11	2018-10-26	复旦大学	吡唑酞嗪化合物及其制备方法和用途
US12605377B2 (en)	2020-10-13	2026-04-21	Endeavor Biomedicines, Inc.	Methods of treating fibrosis
JP2023546536A (ja)	2020-10-13	2023-11-02	エンデバーバイオメディシンズ，インコーポレイテッド	線維症を処置する方法
GEAP202516743A (en) *	2022-09-23	2025-08-11	Merck Sharp & Dohme Llc	Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
WO2025188802A1 (en)	2024-03-05	2025-09-12	Endeavor Biomedicines, Inc.	Methods of improving lung function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1293565A (en) *	1969-05-03	1972-10-18	Aspro Nicholas Ltd	Aminophthalazines and pharmaceutical compositions thereof
ATE203534T1 (de) *	1996-01-15	2001-08-15	Janssen Pharmaceutica Nv	Angiogenesis hemmende pyridazinamine
NZ330571A (en) *	1996-10-01	1999-10-28	Kyowa Hakko Kogyo Kk	Nitrogenous heterocyclic compounds that may contain sulphur or oxygen
US6432970B2 (en) *	1998-04-09	2002-08-13	Johns Hopkins University School Of Medicine	Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
IL138645A0 (en)	1998-04-09	2001-10-31	Univ Johns Hopkins Med	Use of steroidal alkaloid derivatives as inhibitors of hedghog signalling pathways
CA2376210A1 (en)	1999-06-08	2000-12-14	Lorantis Limited	Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
DE60322869D1 (de)	2002-04-22	2008-09-25	Univ Johns Hopkins	Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
AU2003265853A1 (en)	2002-08-29	2004-03-19	Curis, Inc.	Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) *	2003-09-29	2011-11-29	The Johns Hopkins University	Hedgehog pathway antagonists
TW200533356A (en)	2004-02-24	2005-10-16	Mitsubishi Pharma Corp	Fused pyridazine derivatives
EP1745039A4 (en)	2004-05-08	2009-07-22	Neurogen Corp	3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
DK1789390T3 (da) *	2004-09-02	2012-02-27	Genentech Inc	Pyridyl-inhibitorer af hedgehog-signalering
EP1900731A1 (de)	2006-09-07	2008-03-19	Bayer Schering Pharma Aktiengesellschaft	N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
PE20090188A1 (es)	2007-03-15	2009-03-20	Novartis Ag	Compuestos heterociclicos como moduladores de la senda de hedgehog
US8153633B2 (en) *	2007-06-25	2012-04-10	Amgen Inc.	Phthalazine compounds, compositions and methods of use
WO2009035568A1 (en)	2007-09-07	2009-03-19	Amgen Inc.	Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
UA102250C2 (ru)	2008-04-29	2013-06-25	Эли Лилли Энд Компани	Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en)	2008-07-18	2010-02-18	Novartis Ag	Organic Compounds as Smo Inhibitors
MX2011005176A (es)	2008-11-17	2011-05-30	Lilly Co Eli	Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
CA2743483C (en)	2008-11-17	2014-03-11	Eli Lilly And Company	Tetrasubstituted pyridazine hedgehog pathway antagonists
AR077014A1 (es) *	2009-06-19	2011-07-27	Lilly Co Eli	Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

2009
- 2009-10-22 EP EP09740613.6A patent/EP2364185B1/en active Active
- 2009-10-22 CN CN200980143394.3A patent/CN102202737B/zh not_active Expired - Fee Related
- 2009-10-22 WO PCT/US2009/061573 patent/WO2010062507A1/en not_active Ceased
- 2009-10-22 PL PL09740613T patent/PL2364185T3/pl unknown
- 2009-10-22 US US13/122,212 patent/US8404687B2/en not_active Expired - Fee Related
- 2009-10-22 KR KR1020117010063A patent/KR101335746B1/ko not_active Expired - Fee Related
- 2009-10-22 HR HRP20130527AT patent/HRP20130527T1/hr unknown
- 2009-10-22 DK DK09740613.6T patent/DK2364185T3/da active
- 2009-10-22 AU AU2009320251A patent/AU2009320251C1/en not_active Ceased
- 2009-10-22 UA UAA201105364A patent/UA102115C2/ru unknown
- 2009-10-22 JP JP2011534624A patent/JP2012507535A/ja active Pending
- 2009-10-22 PT PT97406136T patent/PT2364185E/pt unknown
- 2009-10-22 ES ES09740613T patent/ES2418479T3/es active Active
- 2009-10-22 BR BRPI0921437A patent/BRPI0921437A2/pt not_active IP Right Cessation
- 2009-10-22 EA EA201170640A patent/EA018931B1/ru not_active IP Right Cessation
- 2009-10-22 NZ NZ591945A patent/NZ591945A/xx not_active IP Right Cessation
- 2009-10-22 CA CA2742539A patent/CA2742539C/en not_active Expired - Fee Related
- 2009-10-22 SI SI200930625T patent/SI2364185T1/sl unknown
- 2009-10-22 MX MX2011004683A patent/MX2011004683A/es active IP Right Grant
- 2009-10-22 PE PE2011000937A patent/PE20110433A1/es not_active Application Discontinuation
2011
- 2011-03-21 IL IL211841A patent/IL211841A0/en unknown
- 2011-04-01 ZA ZA2011/02448A patent/ZA201102448B/en unknown
- 2011-04-07 TN TN2011000166A patent/TN2011000166A1/fr unknown
- 2011-04-15 CR CR20110202A patent/CR20110202A/es not_active Application Discontinuation
- 2011-04-22 MA MA33790A patent/MA32726B1/fr unknown
- 2011-05-02 CL CL2011000979A patent/CL2011000979A1/es unknown
- 2011-05-02 EC EC2011011021A patent/ECSP11011021A/es unknown
- 2011-05-11 CO CO11058054A patent/CO6382123A2/es active IP Right Grant
2013
- 2013-06-05 CY CY20131100447T patent/CY1114023T1/el unknown

Also Published As

Publication number	Publication date
TN2011000166A1 (en)	2012-12-17
KR101335746B1 (ko)	2013-12-12
EP2364185A1 (en)	2011-09-14
HK1159010A1 (en)	2012-07-27
HRP20130527T1 (en)	2013-07-31
CL2011000979A1 (es)	2011-10-07
EP2364185B1 (en)	2013-05-22
IL211841A0 (en)	2011-06-30
AU2009320251B2 (en)	2013-01-24
PL2364185T3 (pl)	2013-10-31
CR20110202A (es)	2011-06-09
MX2011004683A (es)	2011-06-20
AU2009320251C1 (en)	2013-08-15
JP2012507535A (ja)	2012-03-29
DK2364185T3 (da)	2013-06-03
CY1114023T1 (el)	2016-07-27
NZ591945A (en)	2012-10-26
CN102202737B (zh)	2014-03-26
CN102202737A (zh)	2011-09-28
EA018931B1 (ru)	2013-11-29
ES2418479T3 (es)	2013-08-14
KR20110066212A (ko)	2011-06-16
US8404687B2 (en)	2013-03-26
EA201170640A1 (ru)	2011-12-30
CO6382123A2 (es)	2012-02-15
SI2364185T1 (sl)	2013-07-31
UA102115C2 (ru)	2013-06-10
US20110190304A1 (en)	2011-08-04
CA2742539C (en)	2014-05-06
PT2364185E (pt)	2013-07-24
AU2009320251A1 (en)	2010-06-03
BRPI0921437A2 (pt)	2018-10-30
WO2010062507A1 (en)	2010-06-03
ZA201102448B (en)	2012-09-26
PE20110433A1 (es)	2011-07-09
ECSP11011021A (es)	2011-06-30
CA2742539A1 (en)	2010-06-03

Publication	Publication Date	Title
MA32726B1 (fr)	2011-10-02	Antagonistes phtalazine disubstituee de la voie de signalisation hedgehog
MA33363B1 (fr)	2012-06-01	Antagonistes de la voie de signalisation hedgehog a base de phtalazine disubstituee
MA32349B1 (fr)	2011-06-01	Antagonistes de la voie hedgehog a base de phtalazines disubstituees
CY1125421T1 (el)	2025-05-09	Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων
CY1122988T1 (el)	2021-10-29	Υπογλωσσια υμενια
MX2010007867A (es)	2010-08-09	Composiciones de limpieza personal concentradas.
TR200906131T1 (tr)	2009-11-23	Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
CY1112912T1 (el)	2016-04-13	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
MX338884B (es)	2016-05-04	Composiciones y metodos que comprenden variantes de proteasa.
BRPI0814772A2 (pt)	2015-03-03	Indazóis substituídos por 5-piridinona
NO20083492L (no)	2008-10-28	11-Beta HSD1 inhibitorer
EA201171367A1 (ru)	2012-04-30	Винилиндазолильные соединения
EA201101521A1 (ru)	2012-09-28	Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EP2569434A4 (en)	2013-11-20	COMPOSITIONS AND METHODS OF TREATING LEUKEMIA
EA201170699A1 (ru)	2011-12-30	Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
NO20084458L (no)	2008-11-19	IL-8-reseptorantagonister
FR23C1002I2 (fr)	2023-11-24	2,4,6-trifluoro-n-ý6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide destiné au traitement de la migraine par la voie orale ou intraveineuse
EA200971068A1 (ru)	2010-04-30	Триазолиламинопиримидиновые соединения
CY1119800T1 (el)	2018-06-27	Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
EA201170700A1 (ru)	2011-10-31	Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
MX2009012767A (es)	2009-12-10	Metodos de tratamiento de infecciones fungicas.
EA200800342A1 (ru)	2008-08-29	ИНГИБИТОРЫ Glepp-1 ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И/ИЛИ ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
TN2010000489A1 (en)	2012-05-24	Disubstituted phthalazine hedgehog pathway antagonists
CY1115900T1 (el)	2017-01-25	Αντισωματα αντι-ephb4 και μεθοδοι χρησης αυτων
FR2935976B1 (fr)	2010-12-17	Voie courte de synthese du 1,6:2,3-dianhydro-b-d- mannopyranose.